Campuses: FH.com Home button

Clinical Trials Currently Open

Below is the list of clinical trials currently available at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinator at (386) 231-4023.

Clinical trials with Florida Cancer Specialists can be found at www.flcancer.com/trialnavigator

 

Breast Cancer Studies

Alliance/NCI A011401:  Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer - NCT02750826 (FHMMC, Flagler, FISH, Deland)

https://clinicaltrials.gov/ct2/show/NCT02750826

#311-06-EP Breast Cancer Collaborative Registry Trial (BCCR):  A Breast Cancer Information Registry for Participants with Breast Cancer or Characteristics of Hereditary Breast Cancer. (FHMMC, Flagler, FISH, Deland) NCT00666731

BRE 257/FCS A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer-NCT02370238 (FHMMC/Daytona)

BRE 267/FCS Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)- NCT02437318 (FHMMC/Daytona)

 

Lung Cancer Studies

LUN 298/ GO29437:  A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin +Paclitaxel or MPDL3280A In Combination with Carboplatin + Nab-Paclitaxel Versus Carboplatin + Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NCT02367794)

https://clinicaltrials.gov/ct2/show/NCT02367794

LUN 299/GO29537:  A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Nab-Paclitaxel For Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NCT02367781)

https://clinicaltrials.gov/ct2/show/NCT02367781

LUN 308/ GO29527:  A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Atezolizumab, Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Chemotherapy in Patients With Lung Cancer (NCT02486718)

https://clinicaltrials.gov/ct2/show/NCT02486718  (coming soon)


Melanoma Studies

Amgen 20120139:   "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with

 Melanoma Who Previously Received Talimogene Laherparepvec."  NCT02173171 (FHMMC)

MEL 41/FCS:  A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma  NCT01656642  (coming soon FHMMC/Daytona Cancer Ctr.)

 

Glioblastoma Studies

A221101 “A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodfinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma." 

https://clinicaltrials.gov/ct2/show/study/NCT01781468?show_locs=Y#locn

Ovarian Studies

GYN 60/FCS:  A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)  NCT02580058 (FHMMC/Daytona Cancer Ctr.)